NCT05686525 Clinical Trial on the Effectiveness of TUMT Compared to PAE in Reducing Severe LUTS in Men with BPH
| NCT ID | NCT05686525 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Rigshospitalet, Denmark |
| Condition | Prostatic Hyperplasia |
| Study Type | INTERVENTIONAL |
| Enrollment | 220 participants |
| Start Date | 2022-10-27 |
| Primary Completion | 2030-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 220 participants in total. It began in 2022-10-27 with a primary completion date of 2030-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The TUMT-PAE-1 trial is a randomised clinical trial aiming to compare the effectiveness of transurethral microwave thermotherapy (TUMT) with prostatic artery embolisation (PAE) in reducing urinary symptoms caused by prostate gland enlargement. The assessment will be done by patient reported and functional outcome measures. The primary purpose is to evaluate the urinary symptoms six months after the procedure, measured by the International Prostate Symptom Score (IPSS).
Eligibility Criteria
Inclusion Criteria: * Ability to understand and the willingness to sign an informed consent. * Diagnosis of LUTS secondary to BPH refractory to/contraindicated for medical treatment or not patient preference. * Severe urinary symptoms on IPSS (IPSS score ≥ 20). * Bladder outlet obstruction (BOO) is defined by Qmax ≤ 15ml/sec, based on uroflowmetry. * Prostate volume at minimum 50 ml measured by TRUS or MR. * Men with prostate cancer in Active Surveillance or Watchful Waiting who have LUTS due to a large BPH component are allowed. * Indwelling catheter or intermittent catheter is allowed. In this case baseline IPSS is 35 points. Exclusion Criteria: * Active bladder cancer (patients with pTa low-grade tumors are allowed). * Previous pelvic radiation for cancer treatment. * Bladder stones (inclusion is allowed after removal). * Current urethral strictures or bladder neck contracture. * Neurogenic LUTS. * Symptomatic urinary tract infection at the time of intervention. * Documented bacterial prostatitis in the last year. * Severe atheromatous disease or other pathology preventing catheter-based intervention (as rated on CT angiography by an interventional radiologist). * Allergy to iodinated contrast media. * Renal failure defined as estimated glomerular filtration rate (eGFR) \< 35ml/min. * High bleeding risk (spontaneous international normalized ratio (INR) \> 1.6). * Contraindication to conscious sedation (if requested by the patient). * Prostate median lobe defined by treating physician. * Urethral colliculus to bladder neck length \<35mm.
Contact & Investigator
Andreas Røder, Prof.,MD,PhD
STUDY DIRECTOR
Urological Research Unit, Rigshospitalet
Frequently Asked Questions
Who can join the NCT05686525 clinical trial?
This trial is open to male participants only, aged 40 Years or older, studying Prostatic Hyperplasia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05686525 currently recruiting?
Yes, NCT05686525 is actively recruiting participants. Contact the research team at anna.kristensen-alvarez@regionh.dk for enrollment information.
Where is the NCT05686525 trial being conducted?
This trial is being conducted at Copenhagen, Denmark, Gentofte Municipality, Denmark, Roskilde, Denmark.
Who is sponsoring the NCT05686525 clinical trial?
NCT05686525 is sponsored by Rigshospitalet, Denmark. The principal investigator is Andreas Røder, Prof.,MD,PhD at Urological Research Unit, Rigshospitalet. The trial plans to enroll 220 participants.